Description
The CJC-1295 NO DAC and Ipamorelin combination represents a sophisticated research formulation combining two distinct growth hormone secretagogues with complementary mechanisms of action for comprehensive growth hormone research applications. This combination allows for investigation of synergistic effects between growth hormone-releasing hormone (GHRH) and ghrelin signaling pathways, potentially resulting in enhanced and more physiologically relevant growth hormone release patterns compared to single-agent approaches.
CJC-1295 NO DAC represents the standard formulation of the synthetic growth hormone-releasing hormone analogue without Drug Affinity Complex modification. The compound exhibits the molecular formula C165H269N47O46 with a molecular weight of 3647.15 g/mol and consists of 29 amino acids representing a modified version of the first 29 amino acids of endogenous GHRH. The structural modifications incorporated into CJC-1295 include D-alanine at position 2 to enhance resistance to enzymatic degradation, glutamine at position 8 to reduce asparagine rearrangement and prevent amide hydrolysis to aspartic acid, alanine at position 15 to enhance bioactivity, and leucine at position 27 to prevent methionine oxidation. These strategic substitutions collectively contribute to improved stability and extended half-life compared to native GHRH while maintaining the natural pulsatile release pattern characteristic of endogenous growth hormone regulation.
Ipamorelin represents a synthetic pentapeptide growth hormone secretagogue designed to demonstrate selective activity at ghrelin receptors with minimal effects on other hormone systems. The compound functions as a selective ghrelin receptor (GHS-R1a) agonist, demonstrating high binding affinity and activation specificity compared to other growth hormone releasing peptides. This selectivity profile makes ipamorelin particularly valuable for research investigating specific ghrelin receptor signaling pathways without interference from other hormone receptor systems such as cortisol or prolactin receptors.
The combination of CJC-1295 NO DAC and Ipamorelin provides a unique research platform for investigating the interactions between GHRH and ghrelin signaling pathways. CJC-1295 NO DAC functions through specific binding to growth hormone-releasing hormone receptors located in the anterior pituitary gland, leading to activation of adenylyl cyclase and increased cyclic adenosine monophosphate (cAMP) levels. Simultaneously, Ipamorelin activates ghrelin receptors through a distinct G-protein coupled receptor signaling pathway, also resulting in increased cAMP levels but through different receptor mechanisms.
This dual pathway activation allows for investigation of potential synergistic effects between GHRH and ghrelin signaling systems, providing opportunities to study how these complementary mechanisms may work together to optimize growth hormone release patterns. The combination enables research into more physiologically relevant growth hormone secretion profiles that may more closely mimic natural hormone regulation compared to single-agent approaches.
The formulation is particularly valuable for research examining the temporal dynamics of growth hormone release, as the different pharmacokinetic profiles of the two components allow for investigation of both immediate and sustained growth hormone releasing effects. CJC-1295 NO DAC provides sustained GHRH receptor activation while maintaining natural pulsatile patterns, while Ipamorelin contributes selective ghrelin receptor stimulation with minimal side effects on other hormone systems.
Research applications of this combination include investigation of growth hormone physiology, dual receptor pharmacology, and the molecular mechanisms underlying synergistic growth hormone secretagogue activity. The combination allows for examination of how different growth hormone releasing pathways interact and potentially enhance each other’s effects, providing insights into optimal approaches for growth hormone research protocols.
The 5mg + 5mg formulation provides balanced concentrations of both components, allowing for investigation of equipotent effects and optimal ratios for research applications. This balanced approach enables researchers to study the individual contributions of each component as well as their combined effects in laboratory systems.
Research preparations require appropriate reconstitution and storage protocols to maintain the stability and biological activity of both peptide components. The combination requires proper handling procedures consistent with growth hormone secretagogue research standards to maintain molecular integrity and selectivity throughout experimental protocols.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.